Phosphorylation of Nup98 by multiple kinases is crucial for NPC disassembly during mitotic entry

Disassembly of nuclear pore complexes (NPCs) is a decisive event during mitotic entry in cells undergoing open mitosis, yet the molecular mechanisms underlying NPC disassembly are unknown. Using chemical inhibition and depletion experiments we show that NPC disassembly is a phosphorylation-driven process, dependent on CDK1 activity and supported by members of the NIMA-related kinase (Nek) family. We identify phosphorylation of the GLFG-repeat nucleoporin Nup98 as an important step in mitotic NPC disassembly. Mitotic hyperphosphorylation of Nup98 is accomplished by multiple kinases, including CDK1 and Neks. Nuclei carrying a phosphodeficient mutant of Nup98 undergo nuclear envelope breakdown slowly, such that both the dissociation of Nup98 from NPCs and the permeabilization of the nuclear envelope are delayed. Together, our data provide evidence for a phosphorylation-dependent mechanism underlying disintegration of NPCs during prophase. Moreover, we identify mitotic phosphorylation of Nup98 as a rate-limiting step in mitotic NPC disassembly.     

Identification of 2 loci associated with development of myxomatous mitral valve disease in Cavalier King Charles Spaniels

Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs. It is characterized by chronic progressive degenerative lesions of the mitral valve. The valve leaflets become thickened and prolapse into the left atrium resulting in mitral regurgitation (MR). MMVD is most prevalent in small to medium sized dog breeds, Cavalier King Charles Spaniels (CKCS) in particular. The onset of MMVD is highly age dependent, and at the age of 10 years, nearly all CKCS are affected. The incidence of a similar disease in humans-mitral valve prolapse-is 1-5%. By defining CKCSs with an early onset of MMVD as cases and old dogs with no or mild signs of MMVD as controls, we conducted a genome-wide association study (GWAS) to identify loci associated with development of MMVD. We have identified a 1.58 Mb region on CFA13 (P(genome) = 4.0 × 10(-5)) and a 1.68 Mb region on CFA14 (P(genome) = 7.9 × 10(-4)) associated with development of MMVD. This confirms the power of using the dog as a model to uncover potential candidate regions involved in the molecular mechanisms behind complex traits.     

Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice

Bullous pemphigoid (BP) is a subepidermal autoimmune blistering disease of the elderly associated with considerable morbidity and mortality. As unspecific immunosuppressants are still the mainstay of BP therapy, several animal models, based on the passive transfer of autoantibodies or immune cells, have been developed to obtain a better understanding of the pathogenesis of BP and evaluate novel therapeutic interventions. We describe in this study an experimental model inducing BP by immunization of immunocompetent mice with a recombinant form of the immunodominant 15th noncollagenous domain of murine BP180 (type XVII collagen). The homologous noncollagenous 16A domain of human BP180 has previously been identified as an immunodominant region in human BP. Immunization of female SJL/J mice with the murine peptide led to clinical disease within 14 wk in 56% of mice. In contrast, none of the other strains developed blisters despite the presence of autoantibodies. The clinical disease manifested for at least 8 wk without further manipulation. This novel immunization-induced model reflects key immunopathological characteristics of human BP, including binding of complement-fixing autoantibodies along the dermal-epidermal junction, elevated total IgE serum levels, and infiltration of skin lesions with eosinophilic granulocytes. The use of immunocompetent mice and the induction of sustained clinical disease not requiring additional interventions make this immunization-induced mouse model most suitable to further explore the pathogenesis of BP and novel therapeutic interventions for this and other autoantibody-mediated diseases.     

Effect of fatigue on force production and force application technique during repeated sprints

We investigated the changes in the technical ability of force application/orientation against the ground vs. the physical capability of total force production after a multiple-set repeated sprints series. Twelve male physical education students familiar with sprint running performed four sets of five 6-s sprints (24s of passive rest between sprints, 3min between sets). Sprints were performed from a standing start on an instrumented treadmill, allowing the computation of vertical (F(V)), net horizontal (F(H)) and total (F(Tot)) ground reaction forces for each step. Furthermore, the ratio of forces was calculated as RF=F(H)F(Tot)(-1), and the index of force application technique (D(RF)) representing the decrement in RF with increase in speed was computed as the slope of the linear RF-speed relationship. Changes between pre- (first two sprints) and post-fatigue (last two sprints) were tested using paired t-tests. Performance decreased significantly (e.g. top speed decreased by 15.7±5.4%; P<0.001), and all the mechanical variables tested significantly changed. F(H) showed the largest decrease, compared to F(V) and F(Tot). D(RF) significantly decreased (P<0.001, effect size=1.20), and the individual magnitudes of change of D(RF) were significantly more important than those of F(Tot) (19.2±20.9 vs. 5.81±5.76%, respectively; P<0.01). During a multiple-set repeated sprint series, both the total force production capability and the technical ability to apply force effectively against the ground are altered, the latter to a larger extent than the former.     

Arrested oocyst maturation in Plasmodium parasites lacking type II NADH:ubiquinone dehydrogenase

The Plasmodium mitochondrial electron transport chain has received considerable attention as a potential target for new antimalarial drugs. Atovaquone, a potent inhibitor of Plasmodium cytochrome bc(1), in combination with proguanil is recommended for chemoprophylaxis and treatment of malaria. The type II NADH:ubiquinone oxidoreductase (NDH2) is considered an attractive drug target, as its inhibition is thought to lead to the arrest of the mitochondrial electron transport chain and, as a consequence, pyrimidine biosynthesis, an essential pathway for the parasite. Using the rodent malaria parasite Plasmodium berghei as an in vivo infection model, we studied the role of NDH2 during Plasmodium life cycle progression. NDH2 can be deleted by targeted gene disruption and, thus, is dispensable for the pathogenic asexual blood stages, disproving the candidacy for an anti-malarial drug target. After transmission to the insect vector, NDH2-deficient ookinetes display an intact mitochondrial membrane potential. However, ndh2(-) parasites fail to develop into mature oocysts in the mosquito midgut. We propose that Plasmodium blood stage parasites rely on glycolysis as the main ATP generating process, whereas in the invertebrate vector, a glucose-deprived environment, the malaria parasite is dependent on an intact mitochondrial respiratory chain.     

Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1

Proteoglycan (PG) expression was studied in primary human umbilical vein endothelial cells (HUVEC). RT-PCR analyses showed that the expression of the PG serglycin core protein was much higher than that of the extracellular matrix PG decorin and the cell surface PG syndecan-1. PG biosynthesis was further studied by biosynthetic [(35)S]sulfate labeling of polarized HUVEC. Interestingly, a major part of (35)S-PGs was secreted to the apical medium. A large portion of these PGs was trypsin-resistant, a typical feature of serglycin. The trypsin-resistant PGs were mainly of the chondroitin/dermatan sulfate type but also contained a minor heparan sulfate component. Secreted serglycin was identified by immunoprecipitation as a PG with a core protein of ～30 kDa. Serglycin was furthermore shown to be present in perinuclear regions and in two distinct types of vesicles throughout the cytoplasm using immunocytochemistry. To search for possible serglycin partner molecules, HUVEC were stained for the chemokine growth-related oncogene α (GROα/CXCL1). Co-localization with serglycin could be demonstrated, although not in all vesicles. Serglycin did not show overt co-localization with tissue-type plasminogen activator-positive vesicles. When PG biosynthesis was abrogated using benzyl-β-D-xyloside, serglycin secretion was decreased, and the number of vesicles with co-localized serglycin and GROα was reduced. The level of GROα in the apical medium was also reduced after xyloside treatment. Together, these findings indicate that serglycin is a major PG in human endothelial cells, mainly secreted to the apical medium and implicated in chemokine secretion.     

Effectiveness of a quality-improvement program in improving management of primary care practices

Background:

The European Practice Assessment program provides feedback and outreach visits to primary care practices to facilitate quality improvement in five domains (infrastructure, people, information, finance, and quality and safety). We examined the effectiveness of this program in improving management in primary care practices in Germany, with a focus on the domain of quality and safety.

Methods:

In a before–after study, 102 primary care practices completed a practice assessment using the European Practice Assessment instrument at baseline and three years later (intervention group). A comparative group of 102 practices was included that completed their first assessment using this instrument at the time of the intervention group’s second assessment. Mean scores were based on the proportion of indicators for which a positive response was achieved by all of the practices, on a scale of 0 to 100.

Results:

We found significant improvements in all domains between the first and second assessments in the intervention group. In the domain of quality and safety, improvements in scores (mean scores were based on the proportion of indicators for which a positive response was achieved by all of the practices, on a scale of 0 to 100) were observed in the following dimensions: complaint management (from a mean score of 51.2 at first assessment to 80.7 at second assessment); analysis of critical incidents (from 79.1 to 89.6); and quality development, quality policy (from 40.7 to 55.6). Overall scores at the time of the second assessment were significantly higher in the intervention group than in the comparative group.

Interpretation:

Primary care practices that completed the European Practice Assessment instrument twice over a three-year period showed improvements in practice management. Our findings show the value of the quality-improvement cycle in the context of practice assessment and the use of established organizational standards for practice management with the Europeaen Practice Assessment.A variety of quality-improvement initiatives in health care management have been implemented in most health care systems.^1,2 Countries such as Australia, New Zealand, the United Kingdom and the United States have a long tradition in, and established standards for, quality management in primary care. In Canada, such initiatives in primary care are in their infancy, despite support by the federal Primary Health Care Transition Fund since 2000.³ In Ontario, a comprehensive book was recently issued that provides recommendations on practice management and clinical indicators for improving quality in primary care settings in the province.⁴ The indicators were adopted and refined from the Royal New Zealand College of General Practitioners, the Royal Australian College of General Practitioners’ National Expert Committee on Standards for General Practices, the TOPAS–Europe Association European Practice Assessment, the United Kingdom’s Quality and Outcomes Framework and the Canadian Institute for Health Information.In Germany, similar developments took place. In 2005, the German government stipulated that health care providers implement a system of annual assessment of quality management.⁵ One of the systems available to practices is the European Practice Assessment (www.epa-qm.de), a validated instrument based on quality indicators for assessing practice management.⁶ The five key domains of the European Practice Assessment instrument and their respective dimensions are described in Figure 1.Open in a separate windowFigure 1:The domains and dimensions (and number of indicators) of the European Practice Assessment instrument used to measure the quality of practice management in primary care practices. For an example of how the pentagon shape is used to provide feedback to individual practices, see Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.110412/-/DC1). GP = general practitioner.The European Practice Assessment is used to help general practices both assess and improve their quality of practice management set against predefined criteria with embedded quality indicators. The improvement process is ongoing (e.g., through plan–do–study–act cycles⁷): each step is reviewed and redesigned with a view to improving the quality of the end product, thereby fostering continuous improvement.⁸ The multifaceted strategy has three essential components: assessment and feedback using validated instruments based on quality indicators; external support through an outreach educational visit by a trained visitor (physician or nurse) to support the practice in improving areas of management identified by the practice;⁹ and formal accreditation by an external organization.Three requirements have to be fulfilled by practices to receive accreditation: achieve a positive response for more than 50% of the indicators; meet predefined safety indicators (e.g., the vaccination status of staff regarding hepatitis B vaccination is recorded and medical equipment is checked regularly according to national regulations); and highlight areas for continuous quality improvement.Accreditation is one method for assessing and benchmarking the performance of general practice care across a broad range of clinical and organizational domains. It describes a formal process of self-assessment and external and independent peer review to encourage best management practice and can result in recommendations for continuous improvement of safety and quality in the practice.⁸ Practice accreditation can be used for different purposes: quality control, regulation, quality improvement, providing data on performance, and marketing.⁸ In Germany, it is used for quality improvement, leading to a certificate.We conducted a study to determine whether improvements in practice management occurred in general practices that completed the European Practice Assessment twice over three years, compared with general practices that completed the European Practice Assessment once. We focused our analysis on the domain of quality and safety, expecting an association between practice organization and quality improvement.^10,11 We hypothesized that the initial use of the European Practice Assessment and reassessment with it three years later would result in improved scores in the dimensions and indicators within the domain of quality and safety.     

Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease

In this study, we present the first account of pentacycloundecane (PCU) peptide based HIV-protease inhibitors. The inhibitor exhibiting the highest activity made use of a natural HIV-protease substrate peptide sequence, that is, attached to the cage (PCU-EAIS). This compound showed nanomolar IC₅₀ activity against the resistance-prone wild type C-South African HIV-protease (C-SA) catalytic site via a norstatine type functional group of the PCU hydroxy lactam. NMR was employed to determine a logical correlation between the inhibitory concentration (IC₅₀) results and the 3D structure of the corresponding inhibitors in solution. NMR investigations indicated that the activity is related to the chirality of the PCU moiety and its ability to induce conformations of the coupled peptide side chain. The results from docking experiments coincided with the experimental observed activities. These findings open up useful applications for this family of cage peptide inhibitors, considering the vast number of alternative disease related proteases that exist.